TenAces Biosciences
Molecular Glue Therapeutics
Company Overview
Snapshot
Founded in January 2024 by Arnout Schepers, TenAces Biosciences operates with 1–10 employees. The company has secured funding across one round from 2 investors, including AION Labs and Israel Biotech Fund. In January 2024, the company was launched by AION Labs, leveraging machine learning for molecular glue discovery.
Business overview
TenAces Biosciences is a biopharmaceutical company specializing in the development of molecular glue therapeutics. Its core technology involves small molecules that induce or stabilize interactions between E3 ligases and target proteins, accelerating protein degradation. The company utilizes machine learning, 3D modeling, and virtual compound screening to rationally design molecular glues for various diseases, operating within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development.
Strategic signal
In January 2024, AION Labs launched TenAces Biosciences, highlighting a strategic move to leverage machine learning for molecular glue discovery. This signals a growing trend in the biopharmaceutical industry towards integrating advanced computational methods to accelerate drug development, potentially offering a more efficient and targeted approach to therapeutic innovation for investors and corporate innovation teams.
Company Intelligence Q&A
- When was TenAces Biosciences founded?
- TenAces Biosciences was founded in January 2024.
- Who are the founders of TenAces Biosciences?
- Arnout Schepers is the founder and CEO of TenAces Biosciences.
- What is TenAces Biosciences' primary focus?
- TenAces Biosciences focuses on the development of molecular glue therapeutics, utilizing machine learning and 3D modeling for drug discovery.
- Which investors participated in TenAces Biosciences' funding round?
- In January 2024, TenAces Biosciences received funding from AION Labs and Israel Biotech Fund.
- What is the strategic significance of AION Labs launching TenAces Biosciences?
- AION Labs launched TenAces Biosciences in January 2024 to advance molecular glue discovery through machine learning, indicating a strategic investment in AI-driven biopharmaceutical innovation.